Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138353 | 1.00 | OPRK1 (0.42) | OPRK1PDE4BPDE4DOPRM1CYP3A4 | |
| SCHEMBL877167 | 0.94 | PDE4D (0.44) | OPRK1PDE4BPDE4D | |
| SCHEMBL877168 | 0.94 | PDE4D (0.44) | OPRK1PDE4BPDE4D | |
| SCHEMBL2136806 | 0.89 | PDE4B (0.41) | PDE4BPDE4D | |
| SCHEMBL682752 | 0.89 | PDE4B (0.41) | PDE4BPDE4D | |
| SCHEMBL10267192 | 0.88 | CTSB (0.44) | PDE4BPDE4D | |
| SCHEMBL683342 | 0.88 | PDE4B (0.42) | PDE4BPDE4D | |
| SCHEMBL877637 | 0.88 | PDE4B (0.42) | PDE4BPDE4D | |
| SCHEMBL877836 | 0.85 | HCRTR1 (0.41) | PDE4BPDE4DCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL681973 | 0.85 | HCRTR1 (0.41) | PDE4BPDE4DCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | claimed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | claimed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | OPRK1 601/4885PDE4B 2/4885PDE4D 3/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | OPRK1 601/4885PDE4B 2/4885PDE4D 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.